ReviewJournal of neural transmission (Vienna, Austria : 1996)2026
Precision prevention for neurodegenerative diseases: lessons learnt from Alzheimer's disease translated into perspectives for Parkinson's disease.
Review in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Relationship Between Voluntary Rapid Blinking Rate and Future Development of Neurodegenerative Disease.Geriatrics & gerontology international · 2026Article
- A Potential Functional Food-Based Neuroprotective Strategy Using Mulberry Leaf Extract and Trolox Against HFoods (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Population ageing is posing significant challenges for healthcare systems and societies worldwide. Neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, are among the leading contributors to disability, dependence, and healthcare costs in ageing societies. Prevention offers the most sustainable approach to reducing the burden of neurodegenerative diseases. While Alzheimer's disease prevention is already advancing through biomarker-based early detection, identification of modifiable risk factors, and multi-domain interventions, efforts are now turning towards Parkinson's disease, the fastest growing neurodegenerative disorder. Using deeply phenotyped cohorts of patients with Parkinson's disease and people with prodromal stages of neurodegenerative diseases, novel biomarkers have enabled biological classification for improved diagnosis of Parkinson's disease, including early cognitive impairments. The expanding knowledge of Parkinson's disease risk factors is now being translated into primary and secondary prevention concepts within integrated care settings to effectively address the burden of neurodegenerative diseases for the people affected. Integrating biomarker-based risk stratification with scalable life-style based programmes offers a realistic pathway toward precision prevention in Parkinson's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.